Emerald Health Therapeutics Inc fka EMHTF

[Powe]

Shorts looking for a crash in July will be disappointed. This isn’t a newly approved drug to the market that may or may not be accepted by the medical community for whatever reason. EMHTF revenue in September increased 331% y/y without recreational! Occasional pullbacks aside, I fully expect the boom to continue right on into 2019 and beyond.